Why the study?
Ticagrelor use has been restricted due to poor aqueous solubility, prompting the development and evaluation of a formulation to improve oral bioavailability and antiplatelet activity.
Does a novel solid dispersion formulation of ticagrelor improve oral bioavailability and antiplatelet activity compared to the marketed formulation in Sprague Dawley rats?
Population
Sprague Dawley rats
Comparison
Developed ticagrelor formulation (SD1) at 10 mg/kg vs marketed formulation (RLD)
Design
Preclinical pharmacokinetic and ex-vivo pharmacodynamic study
Authors
Loading...
Preclinical Ticagrelor formulation gains leave clinical translation uncertain; leaves open human bioavailability and antiplatelet trials.
Does a novel solid dispersion formulation of ticagrelor improve oral bioavailability and antiplatelet activity compared to the marketed formulation in Sprague Dawley rats?
A novel solid dispersion formulation of ticagrelor significantly improved oral bioavailability and antiplatelet activity in a rat model compared to the marketed formulation.
Srivastava et al. (2025) studied this question.